{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:03Z","timestamp":1790661063992,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Corporation of Long Island"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01129-0","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:35:58Z","timestamp":1732707358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of harm reduction receipt and infectious diseases outcomes in United States Veterans with opioid use disorder and history of injection drug use"],"prefix":"10.1186","volume":"21","author":[{"given":"Khushbu P.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronoma","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audun J.","family":"Lier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"1129_CR1","unstructured":"Daniel M, Richesson D, Magas I, Brown S, Hoenig JM, Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2022 National Survey on Drug Use and Health. 2023. Accessed December 21, 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42731\/2022-nsduh-nnr.pdf"},{"issue":"1","key":"1129_CR2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1080\/07853890.2022.2092896","volume":"54","author":"AS 2 Bennett","year":"2022","unstructured":"2 Bennett AS, Guarino H, Britton PC, et al. U.S. military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts. Ann Med. 2022;54(1):1826\u201338. https:\/\/doi.org\/10.1080\/07853890.2022.2092896","journal-title":"Ann Med"},{"key":"1129_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u201388. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.010","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1129_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.amepre.2019.01.016","volume":"57","author":"LA Lin","year":"2019","unstructured":"Lin LA, Peltzman T, McCarthy JF, Oliva EM, Trafton JA, Bohnert ASB. Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. Am J Prev Med. 2019;57(1):106\u201310. https:\/\/doi.org\/10.1016\/j.amepre.2019.01.016","journal-title":"Am J Prev Med"},{"key":"1129_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.029","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"1129_CR6","doi-asserted-by":"publisher","first-page":"ofac624","DOI":"10.1093\/ofid\/ofac624","volume":"9","author":"AJ Lier","year":"2022","unstructured":"Lier AJ, Vander Wyk B, Di Paola A, Springer SA. Evaluation of the impact of HIV serostatus on the hepatitis C virus care cascade and injection drug use among persons initiating medication treatment for opioid use disorder. Open Forum Infect Dis. 2022;9(11):ofac624. https:\/\/doi.org\/10.1093\/ofid\/ofac624","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"1129_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/cid\/ciy924","volume":"68","author":"LR Marks","year":"2019","unstructured":"Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68(11):1935\u201337. https:\/\/doi.org\/10.1093\/cid\/ciy924","journal-title":"Clin Infect Dis"},{"key":"1129_CR8","doi-asserted-by":"publisher","DOI":"10.7326\/M18-2124","author":"AJ Schranz","year":"2019","unstructured":"8, Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2019;170(1):31\u201340. https:\/\/doi.org\/10.7326\/M18-2124"},{"issue":"4","key":"1129_CR9","doi-asserted-by":"publisher","first-page":"ofz089","DOI":"10.1093\/ofid\/ofz089","volume":"6","author":"PA Leahey","year":"2019","unstructured":"Leahey PA, LaSalvia MT, Rosenthal ES, Karchmer AW, Rowley CF. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infect Dis. 2019;6(4):ofz089. https:\/\/doi.org\/10.1093\/ofid\/ofz089","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1129_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/cid\/ciz869","volume":"71","author":"S Straw","year":"2020","unstructured":"Straw S, Baig MW, Gillott R, et al. Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery. Clin Infect Dis. 2020;71(3):564\u201371. https:\/\/doi.org\/10.1093\/cid\/ciz869","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1129_CR11","doi-asserted-by":"publisher","first-page":"e0129360","DOI":"10.1371\/journal.pone.0129360","volume":"10","author":"H Tookes","year":"2015","unstructured":"Tookes H, Diaz C, Li H, Khalid R, Doblecki-Lewis S. A cost analysis of hospitalizations for infections related to injection drug use at a County Safety-Net Hospital in Miami, Florida. PLoS ONE. 2015;10(6):e0129360. https:\/\/doi.org\/10.1371\/journal.pone.0129360","journal-title":"PLoS ONE"},{"issue":"10","key":"1129_CR12","doi-asserted-by":"publisher","first-page":"ofaa414","DOI":"10.1093\/ofid\/ofaa414","volume":"7","author":"LR Marks","year":"2020","unstructured":"Marks LR, Nolan NS, Jiang L, Muthulingam D, Liang SY, Durkin MJ. Use of ICD-10 codes for identification of injection drug use-associated infective endocarditis is nonspecific and obscures critical findings on impact of medications for opioid use disorder. Open Forum Infect Dis. 2020;7(10):ofaa414. https:\/\/doi.org\/10.1093\/ofid\/ofaa414","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1129_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10461-005-9000-7","volume":"9","author":"A Aidala","year":"2005","unstructured":"Aidala A, Cross JE, Stall R, Harre D, Sumartojo E. Housing status and HIV risk behaviors: implications for prevention and policy. AIDS Behav. 2005;9(3):251\u201365. https:\/\/doi.org\/10.1007\/s10461-005-9000-7","journal-title":"AIDS Behav"},{"issue":"1","key":"1129_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40352-019-0086-9","volume":"7","author":"AK Finlay","year":"2019","unstructured":"Finlay AK, Owens MD, Taylor E, et al. A scoping review of military veterans involved in the criminal justice system and their health and healthcare. Health Justice. 2019;7(1):6. https:\/\/doi.org\/10.1186\/s40352-019-0086-9","journal-title":"Health Justice"},{"issue":"3","key":"1129_CR15","first-page":"348","volume":"40","author":"HS Wortzel","year":"2012","unstructured":"Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348\u201354.","journal-title":"J Am Acad Psychiatry Law"},{"issue":"3","key":"1129_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amepre.2021.08.020","volume":"62","author":"KL Beckman","year":"2022","unstructured":"Beckman KL, Williams EC, Hebert PL, et al. Associations among military sexual trauma, opioid use disorder, and gender. Am J Prev Med. 2022;62(3):377\u201386. https:\/\/doi.org\/10.1016\/j.amepre.2021.08.020","journal-title":"Am J Prev Med"},{"issue":"4","key":"1129_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1177\/1524838019897338","volume":"22","author":"SR Forkus","year":"2021","unstructured":"Forkus SR, Weiss NH, Goncharenko S, Mammay J, Church M, Contractor AA. Military sexual trauma and risky behaviors: a systematic review. Trauma Violence Abuse. 2021;22(4):976\u201393. https:\/\/doi.org\/10.1177\/1524838019897338","journal-title":"Trauma Violence Abuse"},{"key":"1129_CR18","doi-asserted-by":"publisher","first-page":"106036","DOI":"10.1016\/j.addbeh.2019.106036","volume":"99","author":"AS Bennett","year":"2019","unstructured":"Bennett AS, Watford JA, Elliott L, Wolfson-Stofko B, Guarino H. Military veterans\u2019 overdose risk behavior: demographic and biopsychosocial influences. Addict Behav. 2019;99:106036. https:\/\/doi.org\/10.1016\/j.addbeh.2019.106036","journal-title":"Addict Behav"},{"issue":"1","key":"1129_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa040603","volume":"351","author":"CW Hoge","year":"2004","unstructured":"Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa040603","journal-title":"N Engl J Med"},{"key":"1129_CR20","doi-asserted-by":"publisher","unstructured":"McCauley JL, Killeen T, Gros DF, Brady KT, Back SE. Posttraumatic stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clin Psychol (New York). 2012;19(3). https:\/\/doi.org\/10.1111\/cpsp.12006","DOI":"10.1111\/cpsp.12006"},{"issue":"9","key":"1129_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jama.2012.234","volume":"307","author":"KH Seal","year":"2012","unstructured":"Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940\u20137. https:\/\/doi.org\/10.1001\/jama.2012.234","journal-title":"JAMA"},{"key":"1129_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/SAR.S116720","volume":"8","author":"JB Teeters","year":"2017","unstructured":"Teeters JB, Lancaster CL, Brown DG, Back SE. Substance use disorders in military veterans: prevalence and treatment challenges. Subst Abuse Rehabil. 2017;8:69\u201377. https:\/\/doi.org\/10.2147\/SAR.S116720","journal-title":"Subst Abuse Rehabil"},{"issue":"1","key":"1129_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2105\/AJPH.2008.155432","volume":"100","author":"TS Wells","year":"2010","unstructured":"Wells TS, LeardMann CA, Fortuna SO, et al. A prospective study of depression following combat deployment in support of the wars in Iraq and Afghanistan. Am J Public Health. 2010;100(1):90\u20139. https:\/\/doi.org\/10.2105\/AJPH.2008.155432","journal-title":"Am J Public Health"},{"issue":"4","key":"1129_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/ADM.0000000000001134","volume":"17","author":"AH Villamagna","year":"2023","unstructured":"Villamagna AH, Beste LA, Borgerding J, et al. Testing and case rates of gonorrhea, chlamydia, syphilis, and HIV among people with substance use disorders in the Veterans Health Administration. J Addict Med. 2023;17(4):387\u201393. https:\/\/doi.org\/10.1097\/ADM.0000000000001134","journal-title":"J Addict Med"},{"key":"1129_CR25","doi-asserted-by":"publisher","unstructured":"Frost MCCL, Zhang L, Lin LA. Comparison of treatment receipt and hospitalization among patients with stimulant use disorder and\/or opioid use disorder in the Veterans Health Administration. J Addict Med. 2024;18(5):561\u2013566 https:\/\/doi.org\/10.1097\/adm.0000000000001329","DOI":"10.1097\/adm.0000000000001329"},{"issue":"7","key":"1129_CR26","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","volume":"73","author":"DP Serota","year":"2021","unstructured":"Serota DP, Bartholomew TS, Tookes HE. Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in Florida, 2016\u20132017. Clin Infect Dis. 2021;73(7):e1649\u201357. https:\/\/doi.org\/10.1093\/cid\/ciaa1278","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"1129_CR27","doi-asserted-by":"publisher","first-page":"S401","DOI":"10.1093\/infdis\/jiaa238","volume":"222","author":"M Adams","year":"2020","unstructured":"Adams M, Sionean C, Broz D, Lewis R, Wejnert C, Group NS. Serious mental illness among young people who inject drugs: an assessment of injection risks and healthcare use. J Infect Dis. 2020;222(Suppl 5):S401\u201309. https:\/\/doi.org\/10.1093\/infdis\/jiaa238","journal-title":"J Infect Dis"},{"issue":"9","key":"1129_CR28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/09540121.2020.1826329","volume":"33","author":"S Dasgupta","year":"2021","unstructured":"Dasgupta S, Tie Y, Lemons-Lyn A, Broz D, Buchacz K, Shouse RL. HIV-positive persons who inject drugs experience poor health outcomes and unmet needs for care services. AIDS Care. 2021;33(9):1146\u201354. https:\/\/doi.org\/10.1080\/09540121.2020.1826329","journal-title":"AIDS Care"},{"key":"1129_CR29","unstructured":"CDC. Provisional drug overdose death counts, 2021 (updated). National Center for Health Statistics. Accessed December 21, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"1129_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.drugalcdep.2014.03.025","volume":"139","author":"AW Carrico","year":"2014","unstructured":"Carrico AW, Woolf-King SE, Neilands TB, Dilworth SE, Johnson MO. Stimulant use and HIV disease management among men in same-sex relationships. Drug Alcohol Depend. 2014;139:174\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.03.025","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1129_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.drugalcdep.2010.06.014","volume":"112","author":"MM Azar","year":"2010","unstructured":"Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178\u201393. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.06.014","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1129_CR32","doi-asserted-by":"publisher","first-page":"e97596","DOI":"10.1371\/journal.pone.0097596","volume":"9","author":"A Lansky","year":"2014","unstructured":"Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS ONE. 2014;9(5):e97596. https:\/\/doi.org\/10.1371\/journal.pone.0097596","journal-title":"PLoS ONE"},{"issue":"4","key":"1129_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","volume":"1","author":"B Hajarizadeh","year":"2016","unstructured":"Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1(4):317\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(16)30075-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1129_CR34","unstructured":"Hepatits C. Department of Veterans Affairs. Accessed May 10, 2024. https:\/\/www.research.va.gov\/topics\/hep-c.cfm"},{"key":"1129_CR35","unstructured":"UNAIDS. People who inject drugs. The GAP Report 2014: UNAIDS, 2014. Accessed December 21, 2023. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/05_Peoplewhoinjectdrugs.pdf"},{"key":"1129_CR36","unstructured":"CDC, Incidence HIV, Surveillance Report HIV. 2021. Accessed December 21, 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/156513"},{"issue":"Suppl 5","key":"1129_CR37","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1093\/infdis\/jiaa112","volume":"222","author":"SB Lyss","year":"2020","unstructured":"Lyss SB, Buchacz K, McClung RP, Asher A, Oster AM. Responding to outbreaks of human immunodeficiency virus among persons who inject drugs-United States, 2016\u20132019: perspectives on recent experience and lessons learned. J Infect Dis. 2020;222(Suppl 5):S239\u201349. https:\/\/doi.org\/10.1093\/infdis\/jiaa112","journal-title":"J Infect Dis"},{"issue":"3","key":"1129_CR38","doi-asserted-by":"publisher","first-page":"ofaa074","DOI":"10.1093\/ofid\/ofaa074","volume":"7","author":"EF Eaton","year":"2020","unstructured":"Eaton EF, Westfall AO, McClesky B, et al. In-hospital illicit drug use and patient-directed discharge: barriers to care for patients with injection-related infections. Open Forum Infect Dis. 2020;7(3):ofaa074. https:\/\/doi.org\/10.1093\/ofid\/ofaa074","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1129_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11524-005-9021-6","volume":"83","author":"KG Heinzerling","year":"2006","unstructured":"Heinzerling KG, Etzioni DA, Hurley B, Holtom P, Bluthenthal RN, Asch SM. Hospital utilization for injection drug use-related soft tissue infections in urban versus rural counties in California. J Urban Health. 2006;83(2):176\u201381. https:\/\/doi.org\/10.1007\/s11524-005-9021-6","journal-title":"J Urban Health"},{"issue":"4","key":"1129_CR40","first-page":"415","volume":"165","author":"A Palepu","year":"2001","unstructured":"Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415\u201320.","journal-title":"CMAJ"},{"issue":"7","key":"1129_CR41","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/dar.13525","volume":"41","author":"FJ Langham","year":"2022","unstructured":"Langham FJ, Curtis SJ, Tang MJ, et al. Acute injection-related infections requiring hospitalisation among people who inject drugs: clinical features, microbiology and management. Drug Alcohol Rev. 2022;41(7):1543\u201353. https:\/\/doi.org\/10.1111\/dar.13525","journal-title":"Drug Alcohol Rev"},{"issue":"Suppl 5","key":"1129_CR42","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","volume":"222","author":"A Levitt","year":"2020","unstructured":"Levitt A, Mermin J, Jones CM, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. J Infect Dis. 2020;222(Suppl 5):S213\u201317. https:\/\/doi.org\/10.1093\/infdis\/jiaa432","journal-title":"J Infect Dis"},{"key":"1129_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.11.029","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1129_CR44","doi-asserted-by":"publisher","first-page":"ofab633","DOI":"10.1093\/ofid\/ofab633","volume":"9","author":"S Lewis","year":"2022","unstructured":"Lewis S, Liang SY, Schwarz ES, et al. Patients with serious injection drug use-related infections who experience patient-directed discharges on oral antibiotics have high rates of antibiotic adherence but require multidisciplinary outpatient support for retention in care. Open Forum Infect Dis. 2022;9(2):ofab633. https:\/\/doi.org\/10.1093\/ofid\/ofab633","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1129_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/08897077.2019.1640831","volume":"41","author":"A Manhapra","year":"2020","unstructured":"Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41(1):110\u201320. https:\/\/doi.org\/10.1080\/08897077.2019.1640831","journal-title":"Subst Abus"},{"issue":"8","key":"1129_CR46","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27488","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1129_CR47","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among us adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3):e223821. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3821","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1129_CR48","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s11606-023-08027-4","volume":"38","author":"JJ Wyse","year":"2023","unstructured":"Wyse JJ, Shull S, Lindner S, et al. Access to medications for opioid use disorder in rural versus urban veterans health administration facilities. J Gen Intern Med. 2023;38(8):1871\u201376. https:\/\/doi.org\/10.1007\/s11606-023-08027-4","journal-title":"J Gen Intern Med"},{"key":"1129_CR49","doi-asserted-by":"publisher","unstructured":"Becker WC, Krebs EE, Edmond SN et al. A research agenda for advancing strategies to improve opioid safety: findings from a vha state of the art conference. J Gen Intern Med. 2020;35(Suppl 3):978\u201382. https:\/\/doi.org\/10.1007\/s11606-020-06260-9","DOI":"10.1007\/s11606-020-06260-9"},{"issue":"5","key":"1129_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamainternmed.2017.0147","volume":"177","author":"WF Gellad","year":"2017","unstructured":"Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: lessons from the Department of Veterans affairs. JAMA Intern Med. 2017;177(5):611\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2017.0147","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1129_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/10550887.2010.531672","volume":"30","author":"A Fareed","year":"2011","unstructured":"Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey SP. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2011;30(1):27\u201338. https:\/\/doi.org\/10.1080\/10550887.2010.531672","journal-title":"J Addict Dis"},{"issue":"10118","key":"1129_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV Jr., Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-X","journal-title":"Lancet"},{"issue":"10","key":"1129_CR53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa022164","journal-title":"N Engl J Med"},{"key":"1129_CR54","doi-asserted-by":"publisher","first-page":"108852","DOI":"10.1016\/j.jsat.2022.108852","volume":"142","author":"AJ Lier","year":"2022","unstructured":"Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. J Subst Abuse Treat. 2022;142:108852. https:\/\/doi.org\/10.1016\/j.jsat.2022.108852","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"1129_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jsat.2006.04.005","volume":"31","author":"DC Lott","year":"2006","unstructured":"Lott DC, Strain EC, Brooner RK, Bigelow GE, Johnson RE. HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat. 2006;31(2):187\u201394. https:\/\/doi.org\/10.1016\/j.jsat.2006.04.005","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl 1","key":"1129_CR56","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","volume":"56","author":"FL Altice","year":"2011","unstructured":"Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22\u201332. https:\/\/doi.org\/10.1097\/QAI.0b013e318209751e","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1129_CR57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","volume":"78","author":"SA Springer","year":"2018","unstructured":"Springer SA, Di Paola A, Azar MM, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr. 2018;78(1):43\u201353. https:\/\/doi.org\/10.1097\/QAI.0000000000001634","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"1129_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","volume":"84","author":"A Palepu","year":"2006","unstructured":"Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188\u201394. https:\/\/doi.org\/10.1016\/j.drugalcdep.2006.02.003","journal-title":"Drug Alcohol Depend"},{"key":"1129_CR59","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ"},{"key":"1129_CR60","doi-asserted-by":"publisher","unstructured":"Pearce LAMJ, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368. https:\/\/doi.org\/10.1136\/bmj.m772","DOI":"10.1136\/bmj.m772"},{"issue":"9","key":"1129_CR61","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"79","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Hickman CB. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;79(9):979\u201393.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"1129_CR62","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","volume":"37","author":"JTL Grebely","year":"2021","unstructured":"Grebely JTL, Degenhardt L, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;37(1):e107\u201311. https:\/\/doi.org\/10.1093\/cid\/ciaa612","journal-title":"Clin Infect Dis"},{"key":"1129_CR63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.drugalcdep.2020.108116","volume":"213","author":"BTJ Severe","year":"2020","unstructured":"Severe BTJ, Madden L, Heimer R. Co-located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug Alcohol Depend. 2020;213:108\u201316. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108116","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"1129_CR64","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","volume":"71","author":"ES Rosenthal","year":"2020","unstructured":"Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis. 2020;71(7):1715\u201322. https:\/\/doi.org\/10.1093\/cid\/ciaa105","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1129_CR65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/cid\/ciab54","volume":"74","author":"SRWS Bartlett","year":"2022","unstructured":"Bartlett SRWS, Yu A, et al. Impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from the direct-acting antiviral (DAA) era: a population-based study. Clin Infect Dis. 2022;74(4):575\u201383. https:\/\/doi.org\/10.1093\/cid\/ciab54","journal-title":"Clin Infect Dis"},{"key":"1129_CR66","unstructured":"Drug overdose death rates. National Institutes of Health. Secondary Drug overdose death rates. National Institutes of Health 2023. Accessed December 21, 2023. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"1129_CR67","unstructured":"Hawkins EJDK, Gordon AJ. Implementing medication treatment for opioid use disorder in VA facilities. VA Health Systems Research, 2020. Accessed October 29, 2024. https:\/\/www.hsrd.research.va.gov\/publications\/forum\/spring20\/default.cfm?ForumMenu=spring20-3"},{"issue":"11","key":"1129_CR68","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1007\/s11606-021-07305-3","volume":"37","author":"SL Calcaterra","year":"2022","unstructured":"Calcaterra SL, Lockhart S, Callister C, Hoover K, Binswanger IA. Opioid use disorder treatment initiation and continuation: a qualitative study of patients who received addiction consultation and hospital-based providers. J Gen Intern Med. 2022;37(11):2786\u201394. https:\/\/doi.org\/10.1007\/s11606-021-07305-3","journal-title":"J Gen Intern Med"},{"key":"1129_CR69","unstructured":"VA Department of Veterans Affairs. VA equips 200,000 veterans with lifesaving naloxone. VA News. 2019. Accessed July 5, 2024. https:\/\/news.va.gov\/press-room\/va-equips-200000-veterans-with-lifesaving-naloxone\/"},{"key":"1129_CR70","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. https:\/\/doi.org\/10.1136\/bmj.f174","journal-title":"BMJ"},{"key":"1129_CR71","unstructured":"Oliva E, Zhu DT. Identifying Gaps in Veterans Health Administration (VHA) Distribution of Lifesaving Naloxone. VA Office of Research and Development. 2024. Accessed July 5, 2024. https:\/\/www.hsrd.research.va.gov\/publications\/forum\/spring24\/default.cfm?ForumMenu=spring24-4"},{"key":"1129_CR72","unstructured":"CDC. Overdose prevention. Naloxone Dispensing Rate, Maps. 2022. Accessed July 5, 2024. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/naloxone-dispensing-rate-maps.html#:~:text=The overall national rate of,varied widely across the country"},{"key":"1129_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trsl.2021.03.001","volume":"234","author":"AS Bennett","year":"2021","unstructured":"Bennett AS, Elliott L. Naloxone\u2019s role in the national opioid crisis-past struggles, current efforts, and future opportunities. Transl Res. 2021;234:43\u201357. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.001","journal-title":"Transl Res"},{"key":"1129_CR74","unstructured":"Substance Use. Department of Veterans Affairs. 2021. Accessed October 29, 2024. https:\/\/www.mentalhealth.va.gov\/substance-use\/index.asp"},{"key":"1129_CR75","doi-asserted-by":"publisher","first-page":"109878","DOI":"10.1016\/j.drugalcdep.2023.109878","volume":"247","author":"JI Tsui","year":"2023","unstructured":"Tsui JI, Lum PJ, Taylor LE, et al. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. Drug Alcohol Depend. 2023;247:109878. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109878","journal-title":"Drug Alcohol Depend"},{"issue":"9883","key":"1129_CR76","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(13)61127-7","journal-title":"Lancet"},{"issue":"10","key":"1129_CR77","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2105\/AJPH.2018.304561","volume":"108","author":"JL Marcus","year":"2018","unstructured":"Marcus JL, Levine K, Grasso C, et al. HIV preexposure prophylaxis as a gateway to primary care. Am J Public Health. 2018;108(10):1418\u201320. https:\/\/doi.org\/10.2105\/AJPH.2018.304561","journal-title":"Am J Public Health"},{"key":"1129_CR78","doi-asserted-by":"publisher","unstructured":"Shaw GSR, Schmidt HA, Madden A, et al. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery. Harm Reduct J. 2023;20(16). https:\/\/doi.org\/10.1186\/s12954-023-00729-6","DOI":"10.1186\/s12954-023-00729-6"},{"key":"1129_CR79","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drugalcdep.2018.08.01480","volume":"195","author":"SG Sherman","year":"2019","unstructured":"Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148\u201355. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.01480","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1129_CR80","doi-asserted-by":"publisher","first-page":"ofae429","DOI":"10.1093\/ofid\/ofae4298","volume":"11","author":"P Srivastava","year":"2024","unstructured":"Srivastava P, Modi V, Lier AJ. Sexually transmitted infection (STI) incidence, STI screening, and human immunodeficiency virus preexposure prophylaxis uptake in United States veterans with opioid use disorder in Long Island, New York. Open Forum Infect Dis. 2024;11(8):ofae429. https:\/\/doi.org\/10.1093\/ofid\/ofae429","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1129_CR81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-022-00286-6","volume":"17","author":"I Petrakis","year":"2022","unstructured":"Petrakis I, Springer SA, Davis C, et al. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract. 2022;17(1):6. https:\/\/doi.org\/10.1186\/s13722-022-00286-6","journal-title":"Addict Sci Clin Pract"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01129-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:07:46Z","timestamp":1732709266000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01129-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01129-0","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the NVAMC institutional board review (approval number 1683516-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}